By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Research & Development 

3210 Merryfield Row

San Diego  California  92121  U.S.A.
Phone: 858-450-2000 Fax: n/a

At Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.

As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:

• cardiovascular and metabolism,
• immunology,
• infectious diseases and vaccines,
• neuroscience, and
• oncology.

We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.

We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.


Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research.
The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.

Key Statistics

Ownership: Private

Web Site: Janssen R&D


Company News
The Castleman Disease Collaborative Network Announces A Research Collaboration With Janssen R&D To Conduct A Proteomics Study Of Idiopathic Multicentric Castleman Disease 4/12/2017 6:49:43 AM
MorphoSys AG Announces That Its Licensee Janssen R&D Has Reported New Data From Two Phase III Studies Of Guselkumab In Plaque Psoriasis 3/3/2017 7:47:47 AM
Janssen R&D Release: New Results From Second Phase III Study Show Significant Efficacy Of Guselkumab And Superiority Versus Humira In Treatment Of Moderate To Severe Plaque Psoriasis 3/3/2017 6:31:40 AM
Janssen R&D Release: Janssen Human Microbiome Institute Announces Multiple Collaborations To Accelerate The Translation Of Microbiome Science Into Health Solutions 2/2/2017 11:17:28 AM
ChemDiv, Inc. Announces Multi-Year Hit Identification Collaboration With Janssen R&D 1/31/2017 7:24:31 AM
Achillion (ACHN) Scores $15 Million Clinical Milestone From Janssen R&D for the Advancement of JNJ-4178 in Phase 2B 12/28/2016 7:44:56 AM
Janssen R&D Release: Late-breaking Phase 2 Ibrutinib Study In Chronic Graft-Versus-Host-Disease (cGVHD) Showed Complete Or Partial Response In Up To Two-Thirds Of Steroid Dependent Or Refractory Patients 12/6/2016 9:13:22 AM
Janssen R&D Release: Daratumumab (DARZALEX) Combination Therapy Showed Consistent Clinical Benefit For Previously-Treated Patients With Multiple Myeloma 12/6/2016 6:46:43 AM
Janssen R&D Release: Data At American Society of Hematology 2016 Show Strong, Lasting Efficacy Of IMBRUVICA (Ibrutinib) Through Five Years Of Treatment For Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) 12/5/2016 10:08:31 AM
MorphoSys AG Announces That Its Licensee Janssen R&D Has Submitted A Marketing Authorization Application For Guselkumab In Europe 11/28/2016 9:27:51 AM